

Big Pharma Mega-Mergers 1995-2014

<https://marketpublishers.com/r/BE2B7FD69BCEN.html>

Date: December 2009

Pages: 114

Price: US\$ 7,600.00 (Single User License)

ID: BE2B7FD69BCEN

Abstracts

Introduction

Mega-mergers (defined here as M&A events with deal sizes >\$5bn) have been a long-term strategic feature of the pharmaceutical industry and have played a key role in shaping the structure and composition of today's leading companies. Is it possible to quantify exactly how much of Big Pharma's sales growth has been driven by M&A versus how much has been self-produced through organic growth?

Scope

*This report analyzes 22 large scale M&A events that have occurred to date within the Big Pharma peer set over the period 1995-2014

*Datamonitor has identified two distinct classes of M&A event: small/fast growth acquisitions and big/slow growth acquisitions.

*Using these two classes Datamonitor has identified three company-level M&A growth strategies that can be attributed to each of the Big Pharma players:

*In addition to the impact of mega-M&A on sales performance the report also assesses the financial implications associated with different M&A strategies

Highlights

Twenty-two large-scale M&A events (defined as those valued above \$5 billion) have occurred within Big Pharma over 1995-2014. Furthermore, every Big Pharma player has undertaken large scale M&A activity at some stage over this period, thereby illustrating it as an ingrained peer set strategy.

Over the period 1995-2014, Big Pharma prescription pharmaceutical sales are forecast to increase from \$84 billion to \$381 billion, with absolute growth of +\$187 billion provided by M&A activity. In other words, two-thirds (c.63%) of Big Pharma sales expansion over a 20-year period will be driven entirely by M&A activity.

Reasons to Purchase

*Assess how much of Big Pharma's sales growth over 1995-2014 will be driven by M&A versus how much will be self-produced through organic growth.

*Assess how Datamonitor has classified each of the current Big Pharma players by their dominant M&A growth strategy

*Analyze the M&A and organic sales growth profiles for each Big Pharma company over the period 1995-2014

Contents

ABOUT DATAMONITOR HEALTHCARE

About the PharmaVitae team

CHAPTER 1 INTRODUCTION

Scope of analysis

Methodology

Company coverage

Data sources

Re-creating analysis from this report using PharmaVitae Explorer queries

Further reading

CHAPTER 2 EXECUTIVE SUMMARY

Key findings

M&A is the dominant form of Big Pharma sales growth over 1995-2014

c.63% of absolute Rx sales growth contributed by large-scale acquisitions

M&A has allowed Big Pharma sales growth rate to keep pace with overall market...

...while maintaining Big Pharma's overall market share

Since 1995, 22 large scale M&A events have occurred within Big Pharma

Each of the Big Pharma players have implemented large-scale M&A

Acquirer/target company overview

The 22 M&A events can be classified by scale and growth performance

Assessment of M&A size and five-year sales CAGR performance reveals two main acquisition types

Only three M&A events have delivered fast growth performance over subsequent five year period

All fast growth acquisitions share mAb-access characteristic

Roche's acquisition of Genentech has delivered most sustainable revenue growth

Only access to high-growth statins lifts large-scale acquisitions above flat growth threshold

Oncology mAbs to replace statins as leading product type in Rx market

Flat growth for recently acquired Big Pharma companies illustrates that M&A will be insufficient to offset patent cliff decline but scale growth remains imperative

Sales growth potential of large M&A events further diminished by demise of blockbuster growth model

Big Pharma R&D has been unable to keep pace with the acceleration in blockbuster growth driven by M&A

M&A event types illustrate fundamentally different company growth strategies

Big Pharma players who primarily use M&A to 'buy growth'

Big Pharma players who primarily use M&A to 'buy scale'

Big Pharma players who have engaged in >2 mega mergers: 'multi M&A'

Big Pharma players who have primarily avoided mega mergers and stayed 'organic'

Financial performance implications by M&A growth strategy type

Table of Contents

Table of figures

CHAPTER 3 BIG PHARMA M&A ACTIVITY, 1995-2014

Key findings

Big Pharma M&A timeline 1995-2009

M&A is the dominant source of Big Pharma sales growth over 1995-2014

c.63% of absolute Rx sales growth contributed by large-scale acquisitions

M&A has allowed Big Pharma sales growth rate to keep pace with overall market...

...while maintaining Big Pharma's overall market share

Increased scale has driven an expansion of blockbuster portfolios...

...but M&A will not allow Big Pharma to scale the patent cliff

Year-on-year growth analysis illustrates growing influence of M&A but also severity of patent cliff

Big Pharma M&A dependency analysis

Company-level market share analysis

CHAPTER 4 M&A ANALYSIS 1995-2014 BY COMPANY

Key findings

Classification of companies by M&A growth strategy

'Buy Growth' players

Roche-Genentech

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Johnson & Johnson

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Abbott-Solvay

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

'Buy Scale' players

Merck-Schering-Plough

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

GlaxoSmithKline

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Sanofi Aventis

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

AstraZeneca

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Bayer AG

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Multi-M&A players

Pfizer-Wyeth

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Novartis

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Organic growth players

Eli Lilly

Importance of M&A to overall performance

Overview of M&A lineage 1995-2014

Post-M&A performance of acquisitions

Bristol-Myers Squibb

Importance of M&A to overall performance
Overview of M&A lineage 1995-2014
Post-M&A performance of acquisitions

CHAPTER 5 FINANCIAL CONSEQUENCES OF GROWTH, SCALE & ORGANIC STRATEGIES

Key findings
Introduction
Overview of financial and stock market analysis approach
Profit margin (EBIT / Total revenues)
Capital turnover (total revenues / capital employed)
Return on capital employed (EBIT / capital employed)
Market capitalization

CHAPTER 6 APPENDIX

Methodology
Definition of a merger & acquisition event, the mega-M&A threshold and the acquirer/target distinction
Framework for analyzing Big Pharma M&A events over 1995-2014
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer

List Of Tables

LIST OF TABLES

Table 1: Company coverage

Table 2: Big Pharma M&A timeline and overview, 1995-2014

Table 3: Big Pharma M&A timeline and overview, 1995-2014

Table 4: Example of RootCo (DestCo growth

Table 5: Exchange rates, 2009

List Of Figures

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer

Figure 2: Big Pharma Rx pharmaceutical sales (\$m) by source, 1995-2014

Figure 3: Big Pharma Rx pharmaceutical absolute sales growth (\$m) by source, 1995-2014

Figure 4: Rx sales CAGR (%) for total market & Big Pharma peer set, 1995-2008 & 1995-2014

Figure 5: Big Pharma share (%) of total Rx pharmaceutical market by organic/M&A sales, 1995-2008

Figure 6: Lineage of companies with one round of M&A activity

Figure 7: Lineage of companies with two rounds of M&A activity

Figure 8: Lineage of companies with more than two rounds of M&A activity

Figure 9: Scatter chart analysis of acquired companies, 1995-2014

Figure 10: Big Pharma M&A events classified by % relative size of target company by acquiring company & % CAGR of target company (five years post-M&A)

Figure 11: Re-based absolute growth & total Rx revenue performance of Centocor, Knoll and Genentech, 13/19-year post-M&A period (\$m)

Figure 12: Grouped Big Pharma M&A events classified by % relative size of target company by acquiring company & % CAGR of target company (5 years post-M&A)

Figure 13: Global Lipitor and Crestor sales (\$m), 2001-14

Figure 14: Global sales (\$m) of statins (C10A1) and oncology-mAbs (L1X3), 2001-14

Figure 15: Big Pharma blockbuster Rx sales (\$m), 2001-14

Figure 16: Classification of Big Pharma companies by M&A growth strategy

Figure 17: Big Pharma companies classified by M&A growth strategy (by % CAGR of target company [five years post-M&A] and % of total growth due to M&A)

Figure 18: Big Pharma Rx pharmaceutical sales by source (\$m), 1995-2014

Figure 19: Big Pharma Rx pharmaceutical absolute sales growth by source (\$m), 1995-2014

Figure 20: Rx sales CAGR (%) for total market & Big Pharma peer set, 1995-2008 & 1995-2014

Figure 21: Big Pharma share (%) of total Rx pharmaceutical market by organic and M&A sales, 1995-2008

Figure 22: Big Pharma blockbuster Rx sales (\$m), 2001-14

Figure 23: Big Pharma absolute Rx sales growth (\$m) by source and time period, 1995-2014

Figure 24: Big Pharma year-on-year absolute Rx sales growth (\$m) by source,

1996-2014

Figure 25: Percentage of absolute Rx sales growth by source, 1995-2014 (%)

Figure 26: Market share (%) analysis by Big Pharma company, 1995-2008

Figure 27: Classification of Big Pharma companies by M&A growth strategy

Figure 28: Roche absolute growth (\$m) by organic/M&A, 1995-2014

Figure 29: Roche Rx revenues by acquired company, 1995-2014 (\$m)

Figure 30: Roche year-on-year absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 31: Roche acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 32: Johnson & Johnson absolute growth (\$m) by organic/M&A, 1995-2014

Figure 33: Johnson & Johnson Rx revenues by acquired company, 1995-2014 (\$m)

Figure 34: Johnson & Johnson year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 35: Johnson & Johnson acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 36: Abbott absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 37: Abbott Rx revenues by acquired company (\$m), 1995-2014

Figure 38: Abbott year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 39: Abbott acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 40: Merck & Co. absolute growth (\$m) by organic/M&A, 1995-2014

Figure 41: Merck & Co. Rx revenues (\$m) by acquired company, 1995-2014

Figure 42: Merck & Co. year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 43: Merck & Co. acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 44: GlaxoSmithKline absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 45: GlaxoSmithKline Rx revenues (\$m) by acquired company, 1995-2014

Figure 46: GlaxoSmithKline year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 47: GlaxoSmithKline acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 48: Sanofi-Aventis absolute growth (\$m) by organic/M&A, 1995-2014

Figure 49: Sanofi-Aventis Rx revenues (\$m) by acquired company, 1995-2014

Figure 50: Sanofi-Aventis year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 51: Sanofi-Aventis acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 52: AstraZeneca absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 53: AstraZeneca Rx revenues (\$m) by acquired company, 1995-2014

Figure 54: AstraZeneca year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 55: AstraZeneca acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 56: Bayer-Schering absolute growth (\$m) by organic/M&A, 1995-2014

Figure 57: Bayer-Schering Rx revenues (\$m) by acquired company, 1995-2014

Figure 58: Bayer-Schering year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 59: Bayer-Schering acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 60: Pfizer absolute growth (\$m) by organic/M&A, 1995-2014

Figure 61: Pfizer Rx revenues (\$m) by acquired company, 1995-2014

Figure 62: Pfizer year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 63: Pfizer acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 64: Novartis absolute growth (\$m) by organic/M&A, 1995-2014

Figure 65: Novartis Rx revenues (\$m) by acquired company, 1995-2014

Figure 66: Novartis year-on-year absolute growth (\$m) by organic/M&A, 1995-2014

Figure 67: Novartis acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 68: Eli Lilly absolute growth (\$m) by organic/M&A, 1995-2014

Figure 69: Eli Lilly Rx revenues (\$m) by acquired company, 1995-2014

Figure 70: Eli Lilly year-on-year absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 71: Eli Lilly acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 72: Bristol-Myers Squibb absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 73: Bristol-Myers Squibb Rx revenues by acquired company, 1995-2014 (\$m)

Figure 74: Bristol-Myers Squibb year-on-year absolute growth by organic/M&A, 1995-2014 (\$m)

Figure 75: Bristol-Myers Squibb acquired company Rx revenues rebased as % of organic Rx revenues at year of acquisition

Figure 76: Return on capital employed formula

Figure 77: % EBIT / total revenues and % operating costs / total revenues, 2004-08 (weighted three-company average for Growth, Scale and Organic company sets)

Figure 78: Total revenues / capital employed and % goodwill & intangibles / total revenues, 2004-08 (weighted three-company average for Growth, Scale and Organic company sets)

Figure 79: EBIT / capital employed build-up from EBIT margin and capital turnover, 2004-08 (weighted three-company average for Growth, Scale and Organic company sets)

sets)

Figure 80: Market capitalization (indexed Jan 2005), 2005-08 (weighted three-company average for Growth, Scale and Organic company sets 2005-09)

Figure 81: Evolutionary timeline for theoretical company 'RootCo'

Figure 82: Theoretical sales performance for RootCo + Targ1Co & Targ2Co

Figure 83: Disaggregation of sales growth in organic and M&A components

I would like to order

Product name: Big Pharma Mega-Mergers 1995-2014

Product link: <https://marketpublishers.com/r/BE2B7FD69BCEN.html>

Price: US\$ 7,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE2B7FD69BCEN.html>